EGFR and colorectal cancer: MiR-320d has been more extensively investigated in the gut, as it may inhibit the malignant phenotype of EGFR-positive colorectal cancer (CRC) [46] and has been indicated as a putative blood biomarker for the early diagnosis of CRC [47].